Mean serum concentrations of tolterodine and 5-HMT in these elderly volunteers were approximately 20% and 50% higher, respectively, than concentrations reported in young healthy volunteers. Similar percentages of patients treated with tolterodine tartrate extended-release capsules or placebo discontinued treatment due to adverse events. Tolterodine belongs to a class of drugs called cholinergic (acetylcholine) receptor blockers. Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. Do not share it with other people even if they have the same symptoms you have. The child fully recovered.Tolterodine tartrate extended-release capsules contain tolterodine tartrate USP. Tolterodine tartrate is a white, crystalline powder with a molecular weight of 475.6. At these exposure margins, no increase in tumors was found in either mice or rats.No mutagenic or genotoxic effects of tolterodine were detected in a battery of In female mice treated for 2 weeks before mating and during gestation with 20 mg/kg/day (about 9-12 times the clinical exposure via AUC), neither effects on reproductive performance or fertility were seen. Tolterodine tartrate extended release-capsules is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C) [Renal impairment can significantly alter the disposition of tolterodine and its metabolites. There has been no association of Torsade de Pointes in the international post-marketing experience with tolterodine immediate release tablets or tolterodine tartrate extended-release capsules [see A summary of mean (± standard deviation) pharmacokinetic parameters of tolterodine extended release and 5-HMT in extensive (EM) and poor (PM) metabolizers is provided in Table 3. In a study of tolterodine immediate release conducted in cirrhotic patients (Child-Pugh Class A and B), the elimination half-life of tolterodine immediate release was longer in cirrhotic patients (mean, 7.8 hours) than in healthy, young, and elderly volunteers (mean, 2 to 4 hours). It is an antimuscarinic (anticholinergic) agent that blocks the action of a chemical that controls the contractions of the urinary bladder. Dry mouth, constipation, abnormal vision (accommodation abnormalities), urinary retention, and dry eyes are expected side effects of antimuscarinic agents.
For a complete list, ask your doctor or pharmacist.Medicines are sometimes prescribed for conditions that are not in the patient information leaflet. Other drugs can affect how your body handles tolterodine tartrate extended-release capsules.
Patients with CCr<10 mL/min have not been studied and use of tolterodine tartrate extended-release in this population is not recommended [Administer tolterodine tartrate extended-release capsules with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junctionIn a study of the effect of tolterodine immediate release tablets on the QT interval [These observations should be considered in clinical decisions to prescribe tolterodine tartrate extended-release capsules to patients with a known history of QT prolongation or to patients who are taking Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors.After oral administration, tolterodine is metabolized in the liver, resulting in the formation of 5-hydroxymethyl tolterodine (5-HMT), the major pharmacologically active metabolite. The active moiety, tolterodine, is a muscarinic receptor antagonist. Tolterodine is used for a bladder that is overly active with symptoms of leakage, increased frequency of urination, and urgency. There appeared to be a greater QTThis study was not designed to make direct statistical comparisons between drugs or dose levels.